

Open Pharma position statement on open access

Chris Winchester

CEO, Oxford PharmaGenesis

MedComms Networking Brunch, 21 October 2019

Disclosures

- Chris Winchester is an Employee and Director of Oxford PharmaGenesis Ltd, a Director and Shareholder of Oxford PharmaGenesis Holdings Limited and a Director of Oxford Health Policy Forum CIC



Why do we need research transparency?

Approximately **59%** of the public trust research by university scientists 'completely' or 'a great deal' ...

... this falls to just **32%** of the public who report the same trust in research by the pharmaceutical industry



Pharmaceutical companies now disclose the results of nearly all their clinical trials




Why might the public report less trust in pharma?

“ A paywall may restrict the number of readers, and this might NOT help the reputation of the pharmaceutical industry (the mindset of it being a bit secretive). ”

Alan Thomas, Ataxia & Me

Some publishers prevent companies from publishing unrestricted open access



- Journals only offering CC BY open access for research funded by specific non-commercial organizations
- Journals offering CC BY open access to organizations that require it


- In a study of 35 medical journals with a high impact factor, 21 (60%) offered an immediate open access option with a Creative Commons licence
- Of these 21 journals:
 - CC BY was offered by 100% (21/21)
 - CC BY-NC was offered by 19% (4/21)
 - CC BY-NC-ND was offered by 86% (18/21)
- **Only one of these 21 journals potentially offered immediate open access under a CC BY licence to authors irrespective of their funding source**

Our purpose


Open Pharma aims to connect pharma with innovations in publishing to achieve a ...



transparent publishing process ...



with **accessible** outputs ...



that are available **quickly** ...



using an **efficient, sustainable** process



Our workstreams

Open access



Increased readership of research
Increased transparency

Preprints and
post-publication
peer review




Faster dissemination of results
Faster citation and use of results

ORCID, CRediT
and Convey




Increased transparency, reduced administrative burden
More accountability

Layered publication
platforms



Complete information available from a single point
Targeted content for each user group

International Open Access Week, 2019




The launch of the Open Pharma position statement on open access



The launch of the Open Pharma position statement on open access




Open access ensures that the highest quality peer-reviewed evidence is available to anyone who needs it, anywhere in the world



Our objectives

Our immediate priority



Secure authors publishing company-funded research the **same right to publish open access** as authors publishing research funded by other sources




All research to be made **free to read from the date of publication**



Any variant of **Creative Commons** or equivalent licence

Our objectives

Our immediate priority



Secure authors publishing company-funded research the **same right to publish open access** as authors publishing research funded by other sources




All research to be made **free to read from the date of publication**



Any variant of **Creative Commons** or equivalent licence

Our long-term goal



Secure authors publishing company-funded research the **same terms** as authors publishing research funded by other sources



Free to read – **and reuse** – from the date of publication



Sustainable use of **CC BY**

Contributors



Catherine Skobe

Senior Director,
Publications Innovative
Solutions Lead, Pfizer



Chris Rains

Head of GMA
Medical Functions,
Takeda



Chris Winchester

CEO, Oxford
PharmaGenesis



Julie Newman

Associate Director,
HIV, Gilead



Lise Baltzer

Director of Global
Publications, Novo Nordisk



Sarah Sabir

Medical Writer, Oxford
PharmaGenesis



Valerie Philippon

Head, Global Publications,
Takeda



- We thank all supporters and followers of Open Pharma for their valuable input

Endorsed by academics, publishers, biopharmaceutical companies and patients



Individuals

Alan Thomas, Ataxia & Me

Gavin Giovannoni, Barts and the London School of
Medicine and Dentistry

Martin Delahunty, Inspiring STEM

Robert Sim, Department of Respiratory Science,
Leicester University

Pali Hungin, Newcastle University

Kajsa Wilhelmsson, Oxford Health System Reform
Group

Elizabeth Kinder, patient advocate

Richard Stephens, patient advocate

Angela Sykes, Pfizer

Courtney Leo, Pfizer

J. R. Meloro, Pfizer

Ellie Challis, PTEN UK & Ireland

Dermot Ryan, Respiratory Effectiveness Group

Victoria Woods, Quality Improvement Lead – Patient
and Public Engagement, Thames Valley Cancer Alliance
at NHS England

Zbys Fedorowicz, The Care Combine and North West
Anglia, NHS Foundation Trust

Stuart Taylor, The Royal Society

Erik Michels, UCB Pharma

Meredith Hays, Department of Medicine, Uniformed
Services University

Stephen Bradley, University of Leeds

Chas Bountra, Professor of Translational Medicine,
Nuffield Department of Clinical Medicine, University of
Oxford

Edith Sim, Professor Emeritus, Department of
Pharmacology, University of Oxford

Stevan Harnad, University of Southampton

Alvaro Diaz, Departamento de Biociencias, Universidad
de la República de Uruguay

Endorsed by academics, publishers, biopharmaceutical companies and patients



Organizations

Ataxia & Me
Cambridge Rare Disease Network
Galapagos NV
Kidney Research UK
Observational and Pragmatic
Research Institute Pte
Oxford Health Policy Forum
Oxford PharmaGenesis
SUDEP Action
ThinkSCIENCE, Inc.

Publishers

F1000 Research Ltd
Wiley

A reminder about why open access matters

“ I recently met a physician from Southern Africa engaged in perinatal HIV prevention, whose primary access to information was abstracts posted on the Internet. **Based on a single abstract, they had altered their perinatal HIV prevention programme from an effective therapy to one with lesser efficacy.**

Had they read the full-text article they would have undoubtedly realized that the study results were based on short-term follow-up, a small pivotal group [and] incomplete data, and [were] unlikely to be applicable to their country's situation. **Their decision to alter treatment based solely on the abstract's conclusions may have resulted in increased perinatal HIV transmission.** ”

*Professor Arthur Ammann
Co-founder of Global Strategies for HIV Prevention*



Open Pharma needs you!

- Do you agree with our position statement on open access?

Yes	No
Visit the Open Pharma site, review the statement and endorse it Encourage others to do the same, within your organization and on social media	Tell us why

- Help us to share the news!

Sign our position statement today!



 <https://openpharma.blog/>

Get involved with the conversation



@_OpenPharma

#openpharma #OAWeek
#openaccess #openforall





Open Pharma